Health
First-in-human study with novel antisense oligonucleotide proves promising – Medical Xpress
A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans. Inhibition of miR-92a has shown beneficial effects in animal models, including improved vascularization after myocardial infarcti…
A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans. Inhibition of miR-92a has shown beneficial effects in animal models, including improved vascularization after myocardial infarction, and accelerated wound healing, according to the peer-reviewed journal Nucleic Acid Therapeutics.
“Based on documented, promising therapeutic potential, locked nucleic acid (LNA)-based anti-miR-92a was further developed and tested in a f…
-
Business11 hours agoTop brokers name 3 ASX shares to buy next week 25 May 2025
-
General21 hours agoZoe Daniel calls for election recount in Goldstein after final count gives Liberal Party’s Tim Wilson 260-vote lead
-
Noosa News21 hours ago‘Stranded’ Eddie the echidna thought to have swum from Bribie Island’s broken tip
-
Business11 hours agoAre your superannuation fees too high? APRA reveals latest industry medians